Guillain-Barré Syndrome ‘More Common Than Expected’ in Early RSV Vaccine Trial
Reports of the nervous system disorder Guillain-Barré syndrome (GBS) were “more common than expected” in the older adult population who received the new vaccine for respiratory syncytial virus (RSV). The data, reported by the U.S. Centers for Disease Control and Prevention (CDC), matched trial data reported earlier this year.1 GBS is a “polio-like” inflammatory autoimmune […]
CDC Reports Errors in RSV Vaccines Given to Pregnant Woman, Monoclonal Antibody Shots to Children
A new problem involving the RSV (Respiratory Syncytial Virus) vaccines given to adults over age 60 and monoclonal antibody shots given to infants and children has been highlighted in a recent emergency newsletter called the U.S. Centers for Disease Control and Prevention (CDC) Clinician Outreach and Communication Activity, which is distributed to health care providers.1 […]
Twelve Infants Die During Clinical Trials for FDA-Endorsed RSV Drug
On June 8, 2023, the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously (21-0) in favor of AstraZeneca and Sanofi’s new nirsevimab (Beyfortus) monoclonal antibody drug believed to provide protection for infants from respiratory syncytial virus (RSV) disease and other lower respiratory tract infections during their first year of life.1 […]
